A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
← catalyst calendarNCT06109272 · readout ≤ 1,502 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
660estimated
Sites
37
Countries
France, Italy, Puerto Rico +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-11 | actual | When the study began enrolling |
| Primary completion | Sep 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Drug: Livmoniplimab — also filed as ABBV-151
- Drug: Budigalimab — also filed as ABBV-181
- Drug: Durvalumab
- Drug: Atezolizumab
- Drug: Bevacizumab
- Drug: Tremelimumab
Primary outcomes
what the primary-completion date above is the date OFStage 1: Best Overall Response (BOR) per Investigator
measured Through Study Completion, Up to Approximately 56 Months
Stage 2: Overall Survival (OS)
measured Through Study Completion, Up to Approximately 56 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed